Showing 9081-9090 of 20877 results for "".
Gene Therapy Safety in DMD: How to Identify Common Immune Reactions
https://reachmd.com/programs/neurofrontiers/gene-therapy-safety-in-dmd-how-to-identify-common-immune-reactions/35681/Gene therapy for Duchenne muscular dystrophy (DMD) introduces a micro-dystrophin transgene to support improved protein production, but it’s not without serious risks, including myocarditis, hepatic inflammation, and myositis. Here to help raise awareness of the common immune complications associatedNew Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
https://reachmd.com/programs/frontlines-prostate-cancer/new-frontiers-in-the-imaging-and-treatment-of-advanced-prostate-cancer/32221/From PSMA imaging to precision medicine strategies based on molecular drivers, novel diagnostics and therapies are reshaping the way we care for men with advanced prostate cancer. But despite these advancements, certain challenges and unmet needs remain. Joining Dr. Wayne Kuang to talk about these eInvestigating Inebilizumab for Generalized Myasthenia Gravis: Results from MINT
https://reachmd.com/programs/neurofrontiers/investigating-inebilizumab-for-generalized-myasthenia-gravis-results-from-mint/35495/Recently published in The New England Journal of Medicine, the phase 3 Myasthenia Gravis Inebilizumab Trial (MINT) underscores the potential of inebilizumab as a therapeutic option for patients with generalized myasthenia gravis (gMG). This is based on the efficacy findings that inebilizumab signifiUnraveling the Mechanism: How Ocrelizumab Impacts Cortical Lesions in MS
https://reachmd.com/programs/neurofrontiers/unraveling-the-mechanism-how-ocrelizumab-impacts-cortical-lesions-in-ms/32367/While B-cell follicles in the brain’s meninges were previously suspected to drive cortical lesions in multiple sclerosis (MS), studies show ocrelizumab has little impact on B-cell follicles—yet it still significantly reduces cortical lesions. This suggests that another, yet-to-be-understood B-cell-mATTR-CM Screening: How Economic Factors Can Impact Care
https://reachmd.com/programs/heart-matters/attr-cm-screening-how-economic-factors-can-impact-care/32901/Economic factors can limit accessibility to screening for transthyretin amyloidosis. Hear expert insights on potential solutions to these challenges.Cognitive Impairment in MS: Mitigating Impacts to Optimize Brain Health
https://reachmd.com/programs/neurofrontiers/cognitive-impairment-in-ms-mitigating-impacts-to-optimize-brain-health/32370/Learn about how cognitive impairment can affect patients with multiple sclerosis and discover ways to support their cognitive function.Multiple Sclerosis Explained: Understanding Its Epidemiology
https://reachmd.com/programs/neurofrontiers/multiple-sclerosis-explained-understanding-its-epidemiology/32371/Hear about how multiple sclerosis impacts patients, and learn about genetic and environmental factors associated with the onset of the disease.The Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://reachmd.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succeIncreasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
https://reachmd.com/programs/acc-action-center/increasing-the-use-of-sglt2i-and-glp1ra-with-remote-program-in-t2d-high-cv-or-kidney-risk/24310/ACC.24 - Can the way patients are educated and medications prescribed be improved? Alexander Blood shares the results of the DRIVE study.Epoprostenol: A Look at a Last-Line Inhalation Therapy for ARDS
https://reachmd.com/programs/clinicians-roundtable/epoprostenol-a-look-at-a-last-line-inhalation-therapy-for-ards/16291/Learn about the efficacy and safety of inhaled epoprostenol as a last-line treatment strategy for patients with acute respiratory distress syndrome.